Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain.

Comparative Analysis of Primary and Monovalent Booster SARS-CoV-2 Vaccination Coverage in Adults with and without HIV in Catalonia, Spain.

Publication date: Dec 30, 2023

People with HIV (PWH) may be more susceptible to SARS-CoV-2 infection and worse clinical outcomes. We investigated the disparity in SARS-CoV-2 vaccination coverage between PWH and those without HIV (PWoH) in Catalonia, Spain, assessing primary and monovalent booster vaccination coverage from December 2021 to July 2022. The vaccines administered were BNT162, ChAdOx1-S, mRNA-127, and Ad26. COV2. S. Using a 1:10 ratio of PWH to PWoH based on sex, age, and socioeconomic deprivation, the analysis included 201,630 individuals (183,300 PWoH and 18,330 PWH). Despite a higher prevalence of comorbidities, PWH exhibited lower rates of complete primary vaccination (78. 2% vs. 81. 8%, p < 0. 001) but surpassed PWoH in booster coverage (68. 5% vs. 63. 1%, p < 0. 001). Notably, complete vaccination rates were lower among PWH with CD4

Open Access PDF

Concepts Keywords
Bnt162 booster doses
December COVID-19
Hiv HIV
July SARS-CoV-2
Socioeconomic vaccination

Semantics

Type Source Name
disease VO vaccination coverage
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO Ad26.COV2.S
disease VO primary vaccination
disease VO vaccination
disease MESH Sexually Transmitted Diseases
disease MESH AIDS
drug DRUGBANK Coenzyme M
disease MESH Infectious Diseases
drug DRUGBANK Aspartame

Original Article

(Visited 1 times, 1 visits today)